corporate overview

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

Pieris is based in Freising-Weihenstephan, in close proximity to Prof. Dr. Skerra's group at the Technical University of Munich (TUM). Prof. Skerra is inventor of the Anticalin technology and co-founded the company in 2001. Pieris has currently 35 employees.